KALA BIO (NASDAQ:KALA) Share Price Passes Below Fifty Day Moving Average – Time to Sell?

Shares of KALA BIO, Inc. (NASDAQ:KALA) crossed below its 50 day moving average during trading on Tuesday . The stock has a 50 day moving average of $1.51 and traded as low as $0.8703. KALA BIO shares last traded at $0.8987, with a volume of 35,236 shares changing hands.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on KALA. Wall Street Zen upgraded KALA BIO from a “sell” rating to a “hold” rating in a research note on Saturday, August 8th. Weiss Ratings restated a “sell (e+)” rating on shares of KALA BIO in a research report on Wednesday, June 24th. One research analyst has rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, KALA BIO currently has an average rating of “Hold” and a consensus target price of $1,158.33.

KALA BIO Stock Performance

The company has a market cap of $16.25 million, a P/E ratio of -0.01 and a beta of -2.26. The business has a 50 day moving average price of $1.48 and a two-hundred day moving average price of $7.47.

KALA BIO (NASDAQ:KALA) last announced its quarterly earnings data on Wednesday, August 19th. The company reported ($21.32) earnings per share for the quarter, missing the consensus estimate of ($6.00) by ($15.32).

Institutional Trading of KALA BIO

A number of institutional investors have recently modified their holdings of KALA. BlackRock Inc. bought a new stake in shares of KALA BIO in the second quarter worth about $124,000. Renaissance Technologies LLC raised its position in KALA BIO by 920.7% during the 1st quarter. Renaissance Technologies LLC now owns 417,517 shares of the company’s stock valued at $72,000 after purchasing an additional 376,612 shares during the last quarter. Virtu Financial LLC purchased a new stake in KALA BIO in the 4th quarter worth approximately $48,000. Baker BROS. Advisors LP lifted its holdings in KALA BIO by 83.1% in the 4th quarter. Baker BROS. Advisors LP now owns 1,804,055 shares of the company’s stock worth $1,003,000 after buying an additional 818,962 shares during the period. Finally, Jane Street Group LLC bought a new stake in shares of KALA BIO in the 4th quarter worth approximately $80,000. 24.61% of the stock is currently owned by hedge funds and other institutional investors.

KALA BIO Company Profile

KALA Bio (NASDAQ: KALA) is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel therapies for ocular diseases. The company’s proprietary surface charge–based nanoparticle delivery platform is designed to enhance penetration and retention of therapeutic agents on the ocular surface. This technology is the basis for its lead product, Eysuvis (KPI-121 1.0%), an FDA-approved topical corticosteroid for short-term relief of ocular itching associated with allergic conjunctivitis.

Beyond its approved therapy, KALA Bio is advancing a pipeline of investigational drug candidates targeting inflammatory and degenerative eye conditions.